166438-88-6

Basic information

• Product Name: 4-(4-BENZYLPIPERAZIN-1-YL)BENZALDEHYDE
• Synonyms: BUTTPARK 90\12-89;4-(4-BENZYLPIPERAZINO)BENZALDEHYDE;4-(4-BENZYLPIPERAZINO)BENZENECARBALDEHYDE;4-(4-BENZYLPIPERAZIN-1-YL)BENZALDEHYDE;AKOS BB-5496;4-(4-BENZYLPIPERAZIN-1-YL)BENZALDEHYDE, 95+%
• CAS NO: 166438-88-6
• Molecular Formula: C₁₈H₂₀N₂O
• Molecular Weight: 280.36
• Mol File: 166438-88-6.mol
• Article Data: 7

Chemical Properties

• Melting Point: 73-75
• Boiling Point: 446.3 °C at 760 mmHg
• Flash Point: 195.3 °C
• Appearance: /
• Density: 1.155 g/cm³
• Vapor Pressure: 3.68E-08mmHg at 25°C
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-(4-BENZYLPIPERAZIN-1-YL)BENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-BENZYLPIPERAZIN-1-YL)BENZALDEHYDE(166438-88-6)
• EPA Substance Registry System: 4-(4-BENZYLPIPERAZIN-1-YL)BENZALDEHYDE(166438-88-6)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 166438-88-6(Hazardous Substances Data)

Usage

Description

4-(4-Benzylpiperazin-1-yl)Benzaldehyde, with the molecular formula C18H20N2O, is a chemical compound that falls under the category of benzylpiperazines. These are organic compounds characterized by a benzyl group attached to a piperazine ring. Although it is not a widely studied chemical, its primary use is in scientific research as a building block for synthesizing more complex compounds. It also has potential applications in pharmaceutical synthesis and medical research.

Uses

Used in Scientific Research:
4-(4-Benzylpiperazin-1-yl)Benzaldehyde is used as a building block for the synthesis of more complex compounds, contributing to the development of new chemical entities.
Used in Pharmaceutical Synthesis:
4-(4-BENZYLPIPERAZIN-1-YL)BENZALDEHYDE is utilized in the creation of pharmaceuticals, potentially leading to the discovery of new drugs and therapeutic agents.
Used in Medical Research:
4-(4-Benzylpiperazin-1-yl)Benzaldehyde has potential applications in medical research, where it may be explored for its properties and possible uses in the treatment or diagnosis of various medical conditions.

InChI:InChI=1/C18H20N2O/c21-15-17-6-8-18(9-7-17)20-12-10-19(11-13-20)14-16-4-2-1-3-5-16/h1-9,15H,10-14H2/p+1

Upstream product

• 2759-28-6 1-phenylmethylpiperazine 
• 459-57-4 4-fluorobenzaldehyde 
• 1208-03-3 4-(bis(2-chloroethyl)amino)benzaldehyde 
• 100-46-9 benzylamine 

Relevant articles and documents

Novel benzimidazole-acrylonitrile hybrids and their derivatives: Design, synthesis and antimycobacterial activity

This paper reports the synthesis and evaluation of some benzimidazole-acrylonitrile hybrid derivatives for their in vitro antimycobacterial activities against Mycobacterium tuberculosis H37Rv. Among the derivatives studied, 3b was found to be the most active compound with MIC of 0.78 μg/mL against M. tuberculosis. This is a quite good activity compared with ethambutol (MIC = 1.56 μg/mL). Moreover, 3b showed 2.8 log fold reduction in bacterial count of dormant forms of mycobacterium which is more potent than first line drugs isoniazid, ciprofloxacin, rifampicin and moxifloxacin. Having activities against both active and dormant forms of M. tuberculosis, 3b may be a useful candidate for the development of new drugs to treat tuberculosis.

Discovery of potent anti-convulsant carbonic anhydrase inhibitors: Design, synthesis, in vitro and in vivo appraisal

We report the design, synthesis and pharmacological assessment of novel benzenesulfonamide derivatives acting as effective carbonic anhydrase (CA, EC 4.2.1.1) inhibitors. All the synthesized compounds were screened for their CA inhibitory action against four isoforms of human origin (h), i.e. hCA I, hCA II, hCA VII and hCA IX. In-vitro carbonic anhydrase inhibition studies have shown that first series, 4-(2-(4-(4-substitutedpiperazin-1-yl)benzylidene)hydrazinyl)benzenesulfonamides (4a- 4i) bestowed low nanomolar range to medium nanomolar range inhibitors against hCA II and hCA VII, effectively involved in epileptogenesis. Furthermore, compounds belonging to the second series, 4-(2-(4-(4-substitutedpiperazin-yl)benzylidene)hydrazinecarbonyl)benzenesulfonamides (8a-8k) showed effective inhibition against hCA VII, being less effective against other hCA isoforms. Inspiring with obtained CA inhibition results, we have chosen some of the potent hCA II and hCA VII inhibitors (4g, 4i and 8d) to test their anti-convulsant efficacy in MES and sc-PTZ seizure tests in Swiss Albino male mice. In result, these compounds significantly attenuated both electrical (MES) as well as chemical (sc-PTZ) induced seizures. Next, in advance anticonvulsant tests, compound 8d displayed long duration of action in time course study and successfully attenuated MES induced seizure in mice up to 6 h after drug administration without showing neurotoxicity in rotarod test. Moreover, this compound was also found to be orally active and effectively abolished generalized tonic-clonic seizures in male Wistar rats upon oral administration, being non-toxic in sub acute toxicity studies.

Design, synthesis, in silico and biological evaluation of novel 2-(4-(4-substituted piperazin-1-yl)benzylidene)hydrazine carboxamides

A series of novel 2-(4-(4-substituted piperazin-1-yl)benzylidene)hydrazinecarboxamide derivatives has been successfully designed and synthesized to evaluate their potential as carbonic anhydrase (CA) inhibitors. The inhibitory potential of synthesized com